• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention concerns a device for isolation of material, such as medical substances, present in dissolved state in human or animal urine. Said device comprises a urine receiving unit (3), a vaporization chamber (6) being in fluid communication with said urine receiving unit, a vapor evacuation unit being in fluid/vapor communication with said vaporization chamber, means for regulating pressure in the vaporization chamber, means for heating the vaporization chamber, and a waste container (9) for receiving waste from the vaporization chamber. The waste container is in fluid communication with the vaporization chamber. The invention further regards a method for isolation of material, such as medical substances, present in dissolved state in human or animal urine.To be published with Fig. 1
    公开号:SE1551420A1
    申请号:SE1551420
    申请日:2015-11-03
    公开日:2017-05-04
    发明作者:Skogvall Staffan；Axelsson Oskar
    申请人:Pharmalundensis Ab；
    IPC主号:
    专利说明:

    1 DEVICE AND A METHOD FOR ISOLATION OF MATERIAL PRESENT INHUMAN OR ANIMAL URINE TECHNICAL FIELDOn a general level, the disclosure relates to a device and a method for isolation ofmaterial, such as medical substances, present in dissolved state in human or animal urine.
    BACKGROUND Medical substances such as antibiotics, cytostatics and non-steroid, anti-inflammatory drugs are widely used to treat sick persons, and are sometimes alsoused to treat animals. Furthermore, it is commonplace in many countries toadminister antibiotics to healthy animals, for the purpose of making them growfaster. Any administered substances are absorbed into the body of the individual.Here, they circulate for some time and are subsequently excreted in original ormetabolized form, mainly via the urine. The excreted urine eventually enters thewastewater system. Because wastewater treatment plants typically do not havethe capacity to remove medical substances from the incoming wastewater, considerable amounts of medical substances end up in the environment. ln a recent scientific article, entitled “Selective Pressure of Antibiotic Pollution onBacteria of Importance to Public Health”, authored by A.Tello, B. Austin and T.Telfer and published in 2012 on pages 1100-1106 of Environmental HealthPerspectives (Volume 120), it has been shown that even very low concentrationsof antibiotics in the environment can lead to an increased prevalence of antibioticresistant bacteria. Furthermore, it is also quite possible that development ofantibiotic resistance occurs already in the waste water system. ln particular, thepipes of the waste water system contain enormous numbers of bacteria. Whenexposed to antibiotics for a long time, they can become increasingly resistant to the antibiotics. 2Many patients in hospitals are severely ill and are therefore often treated with broad-spectrum antibiotics. lt would be extremely unfortunate if bacteriadeveloped resistance to these especially valuable antibiotics so that they became useless. ln the related context, in a European Union Fact sheet(http://ec.europa_eu/research/fp7/pdf/antimicrobial_resistance_fact_sheet_pdf) it isdisclosed that more than 25 000 people in the EU die each year from infectionscaused by drug resistant bacteria, including multiresistant bacteria, and thatantibiotic-resistant germs are regularly found in many hospitals throughout the EU, infecting 4 million patients every year.
    US3506543 discloses a device and a method of providing potable water fromhuman urine under the conditions found in space travel. US20120055777 dealswith reuse of the fluid fraction of the urine as a flushing liquid for restroom fixtures.However, none of these disclosures address the specific challenges that theremoving of medical substances from urine presents. ln particular, the discloseddevices are structurally unfit to ensure a quality-controlled, effective removal ofmedical substances from the urine in conjunction with an economic handling of the waste.
    WO2014/011111 proposes to employ activated carbon in order to solve theproblem of release of potentially harmful substances into the wastewater system.However, the use of activated carbon for this purpose is ridden with considerabledrawbacks. ln particular and as is known in the art, activated carbon is a lipophilicmaterial with a poor ability to bind to hydrophilic medical substances dissolved inurine. Accordingly, large amounts of activated carbon are required if substantialamounts of urine are to be handled, which requires frequent changes of the activecharcoal filter. A further problem is created hereby as these large amounts ofactivated carbon need to be disposed in a safe and environmentally friendlymanner. Moreover, structural properties of the used device, inter alia the presence of a process reactor comprising an activated carbon bed, create a considerable 3risk of multi resistant bacteria developing in the reactor due to the prolonged contact between bacteria originating from the urine and antibiotics. ln order toavoid this, very frequent replacement of the carbon bed is required. Obviously,this complicates and prolongs the process and reduces the usefulness of the proposed solution. ln addition to the above discussed ways of dealing with the problem of antibioticsbeing released into the environment, and thus contributing to creation ofmulti-resistant bacteria, further methods are known in the art. By way of example, urinesamples containing antibiotics could be UV-treated in order to incapacitate anti-biotics. ln order to disable antibiotics, further methods of radiation- and/or ozonetreatment could be employed. The samples could also undergo a chemicaltreatment, such as hydrolysis or oxidation, having the same purpose. However,each of these methods is associated with considerable problems if used for the purpose discussed in this application.
    On the above background, it is an object of the present invention to provide adevice and a method that alleviate at least some of the drawbacks associated withthe current art. ln particular, main objectives of the present invention are to enablea quality controlled, effective and economic isolation of dissolved substances in the urine.
    SUMMARY OF THE INVENTIONThe above stated objective is achieved by means of the device and the methodaccording to the independent claims, and by the embodiments according to the dependent claims.
    A general object of the disclosure is to isolate unwanted substances that aredissolved in urine by removal of substantial amounts of water from the urine. Thewater is released to the public sewage system. The remaining waste (unwantedsubstances plus urine solutes such as urea plus as little water as possible) may subsequently be incinerated in a high temperature oven or like. 4An effective and economical process requires: - removal of as much water from the urine as possible, water beingsubsequently released to the public sewage system, - presence of as little pollution in the water that reaches the sewage system aspossible, and - production of as little waste as possible.
    The device has several important features which were found to be necessary inorder to get a quality controlled, effective isolation of unwanted substances, and an economic handling of waste. ln one aspect, the present disclosure relates to a device suitable for isolation ofmaterial, in particular medical substances, present in dissolved state in human oranimal urine. The device comprises a urine receiving unit suitable for receivingurine and a vaporization chamber being in fluid communication with the urinereceiving unit. The device further comprises a vapor evacuation unit suitable forreceiving vapor from the vaporization chamber and wherein the vapor evacuationunit comprises a protective structure arranged in fluid communication with thevaporization cham ber. The protective structure feature permeability to vapor whilepassage of mist-building droplets (aerosols) is prevented. ln fluid communicationwith the protective structure there is arranged a condensation unit suitable for receiving vapor from the vapor evacuation unit via the protective structure. ln another aspect of the disclosure, the invention concerns a device suitable forisolation of material, in particular medical substances, present in dissolved state inhuman or animal urine, said device. The device comprises a urine receiving unit,a vaporization chamber being in fluid communication with said urine receivingunit, and a vapor evacuation unit suitable for receiving vapor from saidvaporization cham ber. The device comprises a condensation unit suitable forreceiving vapor from said vapor evacuation unit via said protective structure,means for heating the vaporization chamber, a dosing unit for adding of a non- corrosive anti-foaming agent to said vaporization chamber, a waste container for 5receiving waste generated in the vaporization chamber through vaporization of urine. The container being in fluid communication with said vaporization chamber.The inventive device further comprising the vapor evacuation unit, which in turncomprises a protective structure arranged in fluid communication with saidvaporization cham ber. The protective structure is vapor permeable and prevents passage of mist-building droplets (aerosols) from the vaporization chamber.
    The device may further comprise at least one heater adapted to heat theprotective structure for preventing vapor from condensing at the protective stru ctu re _ The device further comprises means, such as a pump, which reduces pressure inthe vaporization chamber such that a below atmospheric pressure is achieved.This gives a better control of the vaporization process in relation to the boilingpoint of the human or animal urine. This also reduces bad smell emanating out of the vaporization chamber.
    The device may further comprise means for heating the vaporization chamber atleast such that the content of the vaporization chamber may boil at the belowatmospheric pressure created by the means for reducing pressure. The boilingmay be done at a first temperature being sufficient to vaporize said urine and todestroy all living microorganisms present in said urine, The boiling may be done ata first temperature being sufficient to vaporize said urine and the urine may beexposed to a second temperature sufficient to destroy all living microorganisms present in said urine.
    The device may further comprise a dosing unit for adding of a non-corrosive anti-foaming agent to the vaporization chamber in order to prevent foaming and/or corrosion during operation. 6The device may further comprise a waste container for receiving waste generated in the vaporization chamber through vaporization of urine, the container being in fluid communication with the vaporization chamber.
    The device may further comprise a urease dosing unit. The urease dosing unitmay inject a dosage of urease at any step of the process. A dosage may be precalculated or it may be adjusted based on measurements carried out in theprocess. The urease dosing unit may inject a dosage of urease at any step of theprocess. A dosage may be pre-calculated or it may be adjusted based on measurements carried out in the process. ln one embodiment of the disclosure, the urease dosing unit is arranged externallyof the device suitable for isolation of material. This reduces the amount andgeneration of waste considerably prolonging both the operation time of the deviceand use of the waste container before the waste container must be replaced by a new empty one. This also improves the economy of the device.
    The device may further comprise an analytical unit arranged at any stage, eitherupstream or downstream of the protective structure. The analytical unit may beadapted to determine the amount of impurities in a condensate derived from thecondensation unit and/or it may be adapted to determine the amount of impurities in the received urine or in the vaporization chamber. ln one embodiment, the analytical unit may determine the amount of impurities bymeasuring conductivity. ln a further embodiment, the analytical unit maydetermine the amount of impurities by measuring absorbance. ln yet a furtherembodiment, the analytical unit may determine the amount of impurities by measuring conductivity and absorbance. ln a yet further embodiment, the device may comprise a microorganism reduction unit arranged so as to be in fluid communication with the urine receiving unit and 7with the vaporization Chamber. The microorganism reduction unit may be arranged to heat up the received urine to a temperature exceeding 60 OC. ln one embodiment, the non-corrosive anti-foaming agent may comprise at least one of paraffins, fatty acids and tensids. ln one embodiment, the waste container may be releasable attached, sealable and exchangeable. ln one embodiment, the protective structure may comprise a maze structure, a plurality of porous deformable filling bodies or at least one polymer sponge. ln one embodiment, the protective structure may comprise a demister. ln anotherembodiment, the protective structure is a demister. ln yet another embodiment,the protective structure may comprise more than one demister. A first possiblesolution is having more than one protective structure comprising one or moredemisters each according to the invention. Another possible solution according tothe invention is having more than one protective structure, wherein at least oneprotective structure comprises one demister and at least one protective structure comprises more than one demister according to the invention.
    One possible solution according to the invention is having more than oneprotective structure, wherein at least one protective structure is coupled in serieswith at least one other protective structure in the fluid communication with thevaporization cham ber according to the invention. Another possible solutionaccording to the invention is having more than one protective structure, wherein atleast one protective structure is coupled in parallel with at least one otherprotective structure in the fluid communication with the vaporization chamber according to the invention.
    Yet another possible solution according to the invention is having more than one protective structure, wherein at least one protective structure is coupled in parallel 8with at least one other protective structure and at least one protective structure is coupled in series with at least one other protective structure in the fluid communication with the vaporization chamber and according to the invention.
    At least one demister may be arranged, i.e. coupled, in parallel or in series with atleast one other demister in one or more protective structures according to theinvention. One or more demisters may be arranged, i.e. coupled, in parallel and inseries with at least one or more other demisters in one or more protective structures according to the invention.
    Another possible solution is having more than one protective structure comprisingat least two demisters being coupled in parallel with each other according to theinvention. Yet another possible solution is having more than one protectivestructure comprising at least two demisters being coupled in series with eachother according to the invention. Still another possible solution is having morethan one protective structure, wherein each protective structure comprises acombination of at least one demister being coupled in series with at least oneother demister and at least one demister being coupled in parallel with at least one other demister according to the invention. ln one embodiment, the device may be dimensioned and assembled as a unitsuitable for mobility within an indoor environment such as a hospital. This makesthe device according to the invention compact and easy to handle and transportindoor. The device according to the invention is also downscaled in weight, notonly in size/dimensions, so that any transportation and lifting of it is facilitated.This is especially advantageous when moving it between floors by elevator andbetween rooms on the same floor and over doorsteps, which portability is of greatimportance at hospitals to make the use of the inventive device much moreflexible. This downsized device according to the invention also reduces costs asthe number of devices to buy may be held to minimum as one device is easilymoved to another location indoor, e.g. between nursing wards in a hospital or in nursing homes or in eldercares or in welfare centers. This device has the same 9 advantages if utilized in animal breeding facilities and/or in dairy farming when processing animal urine. ln a further aspect of the disclosure, the invention relates to a method for isolation of material, in particular medical substances, present in dissolved state in human or animal urine. The method may comprise one or more of the following steps: receiving urine, transferring the received urine into a vaporization chamber, exposing the urine present in the vaporization chamber to a first belowatmospheric pressure and simultaneously therewith exposing the urine to afirst temperature sufficient to destroy all living microorganisms present insaid urine, adding a non-corrosive antifoaming agent to said vaporization chamber inorder to reduce foaming. evacuating the vapor generated in the vaporization chamber, leading the evacuated vapor through a protective structure which hindersliquid but allows vapor to pass through, condensing vapor downstream of said protective structure and conveying waste generated in the vaporization chamber throughvaporization of urine to a waste container, once said waste meets a predetermined criteria or after a predetermined time period. ln still a further aspect of the disclosure, the invention relates to a method for isolation of material, in particular medical substances, present in dissolved state in human or animal urine, wherein said method comprises following steps: - receiving urine, - transferring the received urine into a vaporization chamber, - exposing the urine present in the vaporization chamber to a first below atmospheric pressure, and simultaneously therewith exposing the urine to temperatures sufficient to vaporize said urine and to destroy all living microorganisms present in said urine, - adding a non-corrosive antifoaming agent to said vaporization chamber in order to reduce foaming,- evacuating the vapor generated in the vaporization chamber,- leading the evacuated vapor through a protective structure which hindersliquid but allows vapor to pass through, - condensing vapor downstream of said protective structure, - conveying waste generated in the vaporization chamber throughvaporization of urine to a waste container, once said waste meets apredetermined criteria or after a predetermined time period, and - heating the protective structure to prevent vapor from condensing at the protective structure. ln one embodiment, the method may further comprise exposing the urine presentin the vaporization chamber to a first below atmospheric pressure andsimultaneously therewith exposing the urine to a temperatures sufficient tovaporize the urine by boiling and destroy all living microorganisms present in saidurine, e.g. a first temperature sufficient to vaporize the urine by boiling and asecond temperature sufficient to destroy all living microorganisms present in said urine. ln one embodiment, the method may further comprise reducing the amount ofurea in the urine held in the vaporization chamber by exposing said urine tourease. ln one embodiment, the step of reducing the amount of urea in the urineheld in the vaporization chamber by exposing said urine to urease is performed by means of arranging an urease dosing unit externally of the device. ln a further embodiment, the method may further comprise condensing the vapordownstream of the protective structure so that the amount of impurities in theevacuated vapor is determined using a condensate of the vapor that passed through the protective structure. 11 ln a yet further embodiment, the step of determining the amount of impurities in the evacuated vapor may comprise measuring conductivity or absorbance. ln a further embodiment, the method may further comprise heating up the received urine to a temperature exceeding 60 °C prior to transferring it further. ln a further aspect of the disclosure, the invention relates to a device suitable for isolation of material, in particular medical substances, present in dissolved state in human or animal urine. The device comprising: a urine receiving unit, a vaporization chamber being in fluid communication with the urinereceiving unit, a vapor evacuation unit suitable for receiving vapor from the vaporizationchamber, means, such as a pump, for regulating pressure in the vaporization,means for heating the vaporization chamber, a dosing unit for adding of a non-corrosive anti-foaming agent to thevaporization chamber and a waste container for receiving waste generated in the vaporizationchamber through vaporization of urine, the container being in fluid communication with the vaporization chamber. ln still a further aspect of the disclosure, the invention relates to a device suitable for isolation of material, such as medical substances, present in dissolved state in human or animal urine, said device comprising: a urine receiving unit, a vaporization chamber being in fluid communication with said urinereceiving unit, a vapor evacuation unit suitable for receiving vapor from said vaporizationchamber, means, such as a pump, for regulating pressure in the vaporization chamber and aiding in conveyance of fluid, 12- means for heating the vaporization Chamber, - a dosing unit for adding of a non-corrosive anti-foaming agent to saidvaporization chamber and - a waste container for receiving waste generated in the vaporizationchamber through vaporization of urine, the waste container being in fluid communication with said vaporization chamber. ln still another embodiment, the device comprises and the method uses at leastone heater for heating the protective structure to prevent vapor from condensingat the protective structure. ln a further embodiment, the heater is arrangedexternally of the device suitable for iso|ation of material. ln yet a furtherembodiment of the device, the heater is arranged externally of the protective structure or integrated in the protective structure. ln an additional em bodiment of the device, the protective structure is at least one demister or comprises at least one demister. lt is to be noted that, where applicable, the method steps do not have to takeplace in the above order. Moreover, the term vaporization is here to be construedas a phase transition from the liquid phase to gas phase either through evaporation or through boiling.
    The beneficial effects of using below atmospheric pressure are the reduction ofthe smelling of urine during evaporation and a reduced fouling on the walls of the vaporization cham ber due to the reduction of the boiling point of urine.
    Protective structure During conducted tests, a protective structure has proven to be a vital feature ineffective removal of dissolved substances from the urine. As is described inExample 1, it was found that when the present machine was operated with aprotective structure, the ability to isolate the antibiotic ciprofloxacine was 50 timesmore effective compared to when a protective structure was not utilized. Further- more, it was found that a simple splash protection in the form of a metal plate in 13front of the vapor outlet was not sufficient. lnstead, a protective structure with the ability to stop small water droplets in the form of aerosol was necessary to achieve an effective isolation of the dissolved Substance.
    A suitable protective structure comprises at least one demister, i.e. a unit made ofthin threads of metal arranged at fixed distances and working as a grid/net/latticefor effectively preventing aerosol/droplets to pass through and enabling only forvapor to pass through the protective structure by enabling only single/separate/individual/solitary molecules of vapor to pass through.
    The device and method according to the invention may utilize at least oneprotective structure to achieve an effective prevention of dissolved undesired substances, in particular medical ones, passing through the device.
    The device and method according to the invention may utilize at least twoprotective structures, either coupled in series and/or in parallel, to improve theprevention of dissolved undesired substances, in particular medical ones, passing through the device.
    The device and method according to the invention may utilize at least twoprotective structures comprising at least one demister each to achieve an effectiveprevention of dissolved undesired substances, in particular medical ones, passing through the device.
    The device and method according to the invention may utilize at least twoprotective structures comprising at least two demisters each to improve theprevention of dissolved undesired substances, in particular medical ones, passing through the device.
    The device and method according to the invention may utilize at least oneprotective structure being arranged in parallel with at least one other protective structure and/or at least one protective structure being arranged in series with at 14least one other protective structure, wherein each protective structure comprises at least one demister to achieve an effective prevention of dissolved undesired substances, in particular medical ones, passing through the device.
    The inventors have performed tests with and without any protective structure, e.g.any demister. The tests showed unexpectantly that at least one protectivestructure, e.g. at least one demister, in the device according to one aspect of theinvention, is effective in preventing aerosols/droplets to pass through but reducesthe vaporization rate in the device. A device for testing of this aspect of theinvention vaporized 1.3 litres of fluid/hour without a protective structure and only0.5 litres of fluid/hour with a protective structure. The reason for this is that vaporand aerosol condense in the protective structure and flows back to the vaporization cham ber of the device.
    However, the inventors have surprisingly discovered that another aspect of theinventive device maintain or even improve the prevention of aerosols/dropletsfrom passing through the protective structure but also increases the vaporizationrate of the device at the same time. This aspect concerns heating a protectivestructure, e.g. a demister, so that the above condensing is eliminated or at leastreduced in the protective structure, whereby the vaporization rate of the device then is about or at least 1.1 litres of fluid/hour.
    The heating of at least one protective structure and/or at least one demister are/isachieved by arranging a heating element on the protective structure or thedemister to heat it by being thermally connected therewith. The heating could alsobe achieved by arranging a heating element or heater externally of the protectivestructure and/or the demister to heat either the protective structure or the demisteror both entities, e.g. electrically. The heating is possible to achieve by electrical means and/or heat exchanging.
    Urease unit to reduce waste productionUrine contains 37.1 g solutes/liter and of that 13.4 g is urea (Puttman DF, Composition and concentrative properties of human urine, NASA July, 1971). ln order to reduce the amount of waste, urease was used. A urease dosing unit may be present either upstream of the vaporization chamber, in the vaporizationchamber or in the waste container. Urease converts urea to ammonium ions andcarbon dioxide that is in gaseous state. ln this way, the amount of solid-state waste material may be further reduced by up to about 30 %.
    By use of urease, waste is reduced in any device according to the invention, alsoin devices not having a protective structure according to the invention. For somedevices according to the invention, there may be no need for any protectivestructure as the added urease by itself reduces generated waste amounts. How-ever, a protective structure is very advantageous in the smaller sized deviceaccording to the invention. Alternatively, as a further improvement of the deviceaccording to the invention, a protective structure combined with addition of ureasereduces the amount of generated waste even further. This also aids in making acleaner condensate. Less waste reduces the cost for incineration of waste andalso for service/maintenance personnel due to need of fewer people handling thisand due to a decreased cost for each waste container being recyclable and re- usable.
    The inventors have performed tests to clarify that if addition of external urease isused, this usage is able to reduce the production of waste material from themachine/device to a great extent. ln tests, 10 liters of urine were collected and fedto the evaporator. After all the water had been vaporized, this resulted in anamount of 3 dl waste. After cleaning of the device, another 10 liters of urine wasadded. However, before this urine was added to the device, this urine had beentreated with 100KU Urease (100 000 units/gram solids) from Canavalia ensiformisfor 30 minutes. Then, after evaporation of all the water in the urine, 2 dl wasteremained. Thus, treatment with external urease reduced the waste production byabout 30 % compared to for example spontaneously generated urease producingbacteria that can simply not reduce the amount of waste to the extent and with therepeatability as achieved by the inventive device and method, especially not in humans. 16Analytical unit to evaluate the purity of the vapor and provide quality control of the process ln order to make sure that the vapor from the vaporization chamber is sufficientlyclean, an analytical unit to evaluate the purity was used. This was done eitherthrough measuring conductivity of condensed vapor or by determining itsabsorbance. The calculated data may be registered, stored and/or presented tothe device operator via the control panel. The device may have online monitoringof the quality of the isolation process. This continuous quality control ensures thatthe condensed vapor from the device is sufficiently pure to be released in the public sewage system.
    Microorganism sterilization unitlauxiliary heating unit Urine may contain harmful microorganisms such as bacteria and viruses. Thismay result in a health hazard to humans that for instance are changing wastecontainer. lt is possible that the heating in the vaporization chamber is notsufficient to kill hardy microorganisms such as tuberculosis in spore form. ln orderto kill all microorganisms, a separate auxiliary heating unit may be employed. lnthis application, the terms auxiliary heating unit and microorganism sterilizationunit are interchangeably used. Said unit heats the urine to at least 60° C for asufficient time period in order to kill the microorganisms. lt may also add anti- bacterial chemicals such as hydrogen peroxide for this purpose.
    Non-corrosive antifoaming agent unit When urine boils it results in the generation of significant amounts of foam, whichmay negatively affect the normal function of this device. US3506543 disclose theuse of 3 % sulphuric acid to reduce foaming. However, this acid may corrode thestainless steel of the device and reduce its useful life. Therefore, a non-corrosive,antifoaming agent based on paraffins, fatty acids and tensids was used (hebro®d-foam 2060).
    Further advantages and features of em bodiments will become apparent in the following detailed description in conjunction with the drawings. 17BRIEF DESCRIPTION OF THE DRAWINGS Fig. 1 is a perspective view of a device for use in a care institution and according to an embodiment of the present invention.
    Fig. 2a is a schematic, cross-sectional view showing the protective structure being part of a device according to one embodiment of the present invention.
    Fig. 2b is a schematic, cross-sectional view showing the protective structure being part of a device according to another embodiment of the present invention.
    Fig. 3 is a schematical visualisation of a process performed by a device according to an embodiment of the present invention.
    Figs. 4A and 4B show flow charts of methods for iso|ation of material, in particularmedical substances, present in dissolved state in human or animal urine according to the invention.
    DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS Fig. 1 is a perspective view of a device 1 for use in a care institution, such as anintensive care unit or a unit for treatment of infectious diseases, and according toan em bodiment of the present invention. More specifically, different parts of thedevice 1 are shown. ln this context, it is to be noted that pipes that in thisembodiment would ensure fluid communication between different parts of thedevice have been left out from Fig. 1. Said parts are mounted on a base structure2 comprising a first section 2a extending in a substantially horizontal plane and asecond section 2b extending in a substantially vertical plane. The first section 2ahas a first face that faces parts of the device, and a thereto opposite second face.Analogously, the second section 2b has a first face that faces parts of the device and a thereto opposite, second face. 18Four peripherally positioned casters 4 are attached to the first section. The casters make the device 1 easily movable. A control cabinet 16 and a theretoassociated control panel 17 are affixed to the second section 2b, more particularly to its second face. These components will be discussed in detail further below.
    A funnel-shaped urine receiving unit 3, typically made in stainless steel, is via anarm attached to the second section 2b. ln this context, the urine receiving unit 3may be embodied in different ways e.g. as a cylinder, a parallelepiped or a pipe.The unit may further comprise a hinged lid 11 that prevents inadvertent ejection ofthe urine e.g. due to sudden movements of the device. Urine is typically manuallyfed into the unit from a potty, a catheter bag or similar device. Urine from thereceiving unit is transferred to the vaporization chamber 6. The vaporizationchamber is typically made in stainless steel but may also be made from othermaterial such as plastic or carbon fiber. ln the same context, its top surface 14 isprovided with a plurality of pipe connections. lts bottom surface is also providedwith a pipe connection. For use in hospital environment the capacity of thechamber 6 is usually approximately 10 liters, but other values are conceivable.The chamber 6 is provided with at least one sensor for measuring process properties. ln a variant, the vaporization chamber 6 is also provided with stirring means (notshown) that in an exemplary embodiment are embodied as a centrallyjournalledarm rotating in a horizontal plane. ln some embodiments the stirring is achieved by means of magnetic forces.
    The vaporization chamber 6 may be heated in different ways. ln one embodiment,its walls are heated and the heat is subsequently conductively transferred to theurine in the chamber. ln an alternative embodiment, a dedicated heating elementmay be at least partially immersed in the urine contained in the chamber. lt is alsoenvisaged to supply heat to the chamber via a medium such as water or steam.The vaporization chamber is, during operation, kept at below atmospheric pressure. This is achieved by use of a pump 15. The pump also assists the 19transferring of urine between different receptacles of the device by creating pressure differences. ln one embodiment, the pump 15 is a liquid ring pump. Thechoice of this type of pump entails that the vapor from the vaporization chamber 6may condense in the pump itself. As an alternative, a diaphragm pump or anyother type of pump may be used. The pump is typically powered by a motor. Awaste container 9 for receiving isolated material from the vaporization chamber 6is releasably attached to the first section 2a of the base structure 2. lt may beimmobilized relative the base structure 2 by means of straps or similar locking means. The container is advantageously made in a suitable polymer material.
    A control cabinet 16, shown in Fig. 1, comprises a control unit. The control unittypically has a memory unit (not shown) and a processing unit (not shown) that isconnected to the memory unit. The memory unit could be of the non-volatile kind,such as a flash memory or a RAM (Random Access Memory). A dedicated,executable computer program with computer instructions may be located in thememory unit. The processing unit is configured to carry out the instructions of thecomputer program. The computer program could be recorded on a carrier,typically a computer readable medium, prior to being loaded onto the memoryunit. Alternatively, it could be preinstalled in said memory unit. The disclosedembodiments of the method are performed when the computer programs areexecuted such that above-mentioned instructions are carried out by the suitablyconfigured processing unit. A control panel 17 is associated to the control cabinet16. The control panel 17 is the interface between the operator of the device and the device 1.
    Optional unit 12 is a buffer unit which renders the vaporization process at handmore stable by compensating for eventual disturbances in the feed of urine.
    Fig. 4B is a flow chart of the method for isolation of material, in particular medicalsubstances, present in dissolved state in human or animal urine according to oneembodiment of the invention. The method is used in a device 1 that has beendescribed in connection with Figs. 1-3. The device 1 according to the invention may comprise an urease dosing unit for adding of urease to said vaporization chamber 6. This adding of urease may be done before any waste from the vaporization cham ber is received by the waste container 9, the waste beinggenerated in the vaporization chamber through vaporization of urine. The wastecontainer 9 being in fluid communication with said vaporization chamber 6. Theurease dosing unit may be arranged internally of the device 1 or externally of thedevice or at least one urease dosing unit may be arranged internally of the device and at least one urease dosing unit may be arranged externally of the device.
    The method flow chart in Fig. 4B according to the invention comprises followingsteps: receiving S10 urine, transferring S20 the received urine into thevaporization cham ber 6; exposing S40 the urine to temperatures sufficient tovaporize said urine and to destroy all living microorganisms present in said urine;evacuating S60 the vapor generated in the vaporization chamber; reducing S65the amount of urea in the urine held in the vaporization chamber by exposing saidurine to urease; and conveying S90 waste generated in the vaporization chamberthrough vaporization of urine to the waste container 9, once said waste meets a predetermined criteria or after a predetermined time period.
    The step S65 of reducing the amount of urea in the urine held in the vaporizationchamber 6 by exposing said urine to urease is performed by means of arrangingan urease dosing unit internally or externally of the device 1. The technical effectof adding urease to the urine, preferably, by addition of external urease, this usage of urease is able to reduce the production of waste from the device 1 to a great extent.
    The device 1 further comprises a protective structure 21 (shown in Figs. 2a and2b) which hinders liquid (such as aerosol drops) but allows vapor to pass through.Figs 2a and 2b show cross-sectional views of two embodiments of the protectivestructure 21 according to the present invention. The structure 21 creates aphysical obstacle that hinders liquid (such as aerosol drops), but allows vapor topass through. There is an optional condensation unit 24 to cool vapor from the vaporization cham ber 6. The protective structure 21 is arranged in connection with 21a vapor evacuation unit 7 and is in fluid communication with the vaporization chamber 6. The protective structure 21 is vapor permeable. The protectivestructure 21 is vapor permeable and prevents passage of mist-building droplets (aerosols). The protective structure 21 is liquid-hindering but vapor-pervious.
    Non-limiting examples of the protective structure 21 may in some embodimentscomprise a plurality of porous, deformable filling bodies shown in Fig. 2a. By wayof example, such bodies may be made of steel wool or polymer sponge or acorresponding porous material that hinders liquid but is permeable to gas. lnfurther embodiments, the protective structure may comprise a metal net with aspecified distance between the threads, such as a demister. ln this context and asis known to the person skilled in the particular technical field, these bodies couldbe em bodied and arranged in many different ways. Hence, typical filling bodiesmay also include shapes such as saddles or rings, which may comprise packing,e.g. structured or knitted packing. Simple baffles are also envisaged. Analternative embodiment of the protective structure 21 is shown in Fig. 2b.According to this embodiment, the protective structure 21 may comprise a number of substantially two-dimensional, rigid objects for instance extending radially.
    According to the invention, the device 1 may be provided with more than oneprotective structure 21. ln other embodiments, the device 1 may be provided withat least one protective structure 21 comprising a demister or may be provided withat least one protective structure 21 being a demister in itself. ln yet anotherembodiment, the device 1 may be provided with at least one protective structure21 comprising a demister and at least one protective structure 21 being ademister in itself. ln still other em bodiments, the device 1 may be provided with atleast one protective structure 21 comprising more than one demister or may be provided with more than one protective structure 21 being a demister in itself.
    The technical effect to be achieved by introducing a protective structure 21according to the present invention is the prevention of small, mist-building droplets (aerosol) that are created in the vaporization process, and possibly contain 22chemicals that are intended to be isolated in the vaporization chamber 6, from leaving the latter. Vapor that passed through the protective structure 21 mayoptionally condense in a condensation unit 24 for subsequent release into the waste water system.
    Hence, the technical effect to be achieved by introducing at least one protectivestructure 21 according to the present invention is the prevention of small, mist-building droplets (aerosol) that are created in the vaporization process anddragged along with the generated vapor, e.g. by adhering to droplets and/or bybeing part of the water forming the droplet at vaporization. The droplets/aerosolcarried by the vapor comprise non-fluidic, i.e. solid, fractions in the form ofchemicals comprising medical substances, such as antibiotics, cytostatics andnon-steroid, anti-inflammatory drugs intended to be isolated in the vaporizationchamber 6, which substances then are prevented from leaving the latter and ending up in the drain and let out according to the invention.
    Surprisingly, test results presented in Example 1 below show a 50-fold increase inisolation efficiency of aerosol/droplet carried substances in the vaporizationchamber 6 when at least one protective structure 21 was utilized, compared to when no protective structure 21 was used.
    Fig. 3 highly schematically shows one embodiment of the device with a urinereceiving unit 3, vaporization chamber 6, means 15 for control of the pressure inthe vaporization chamber, e.g. by achieving a below atmospheric pressure,means 31 for heating of the vaporization chamber 6, evacuating the vaporgenerated in the vaporization chamber through the vapor evacuation unit 7,prohibiting liquid, in particular aerosol/droplets comprising unwanted medicalsubstances as defined above, to leave the vaporization chamber by the protectivestructure 21, once the material still present in the vaporization chamber 6 meets apredetermined criteria or after a predetermined time period, evacuating this material from the vaporization chamber to the waste container 9. 23Furthermore, the device comprises a condensation unit 24, an analytical unit 27 to evaluate the cleanness of the vapor, a pump 15 to generate below atmosphericpressure and effluent to the sewer system. ln addition, there are several valvesV1 to V7 that, together with the pump, are used to create differences in internalpressure at least between the urine receiving unit, the vaporization chamber 6, thewaste container 9 and the effluent to the sewage system such that the createdpressure differences at least assist in transferring content at least between theurine receiving unit 3, the vaporization chamber, the waste container 9 and the sewage effluent.
    The analytical unit 27 is configured to determine the amount of impurities presentin the condensed vapor either through measuring conductivity of the condensedvapor and/or by determining its absorbance. The analytical unit 27 is arrangedeither in connection with or downstream of the condensation unit 24. Further, thedevice may feature a pressure gauge 25, a temperature sensor 26, a furthermeans for measuring conductivity and/or absorbance, e.g. via the analytical unit27, a first drain 28, cooling water 29, a sample 32, a second drain 33 and levelsensors N1-N2. The valves V1 to V7 that are adapted to aid and enable control avfluid; waste and vapor flow in the device 1 are not explained in detail as use of such valves is common knowledge for the skilled person.
    Once the waste container 9 is filled, it is removed and its content incinerateddestroying all isolated harmful substances, in particular medical substances that otherwise would have been let out into the sewage together with the condensate.
    Fig. 4A is a flow chart of the method for isolation of material, in particular medicalsubstances, present in dissolved state in human or animal urine according to oneembodiment of the invention. The method is used in a device that has beendescribed in connection with Figs. 1-3. The method comprises receiving urineS10, transferring the received urine into a vaporization chamber 6 (S20), exposingthe urine present in the vaporization chamber to a controlled pressure (e.g. below atmospheric pressure) S30, produced by the pump 15, and simultaneously 24therewith, exposing the urine to a temperature sufficient to vaporize said urine S40 and to destroy living microorganisms present in the urine; adding S50 a non-corrosive antifoaming agent to the vaporization chamber in order to reducefoaming; evacuating the vapor generated in the vaporization chamber S60;leading the evacuated vapor through the protective structure 21 hindering liquid,in particular aerosol droplets, but allowing vapor to pass through S70; condensingS80 vapor downstream of the protective structure; and once the material stillpresent in the vaporization chamber meets a predetermined criteria or after apredetermined time period; evacuating this material/waste from the vaporizationchamber S90.
    The device 1 according to the invention comprises at least one heater 40 forheating at least one protective structure 21 and/or at least one demister 21 to atemperature sufficient to prevent vapor from condensing at the protectivestructure. The method according to the invention comprises a step S100 ofheating at least one protective structure 21 to a temperature sufficient to preventvapor from condensing at each protective structure, e.g. by means of at least oneheater 40 for each protective structure and/or demister 21. The heater 40 mayheat the protective structure and/or demister 21 indirectly and/or directly to atemperature sufficient to prevent vapor from condensing on and/or in and/or at the protective structure and/or on and/or in and/or at the demister 21.
    According to one embodiment of the invention, at least one heater 40 is arrangedexternally of the device 1 suitable for isolation of material. ln another embodiment,at least one heater 40 is arranged externally of at least one protectivestructure/demister 21 of the device 1. ln yet another embodiment, at least oneheater 40 is integrated in at least one protective structure/demister 21 of thedevice 1. The same number of and operational and physical/technical couplingcombinations of heater/-s 40 and/or protective structure/-s and/or demister/-s 21 are applicable for usage in the method according to the invention. ln one embodiment of the invention, the heating to prevent aerosol and/or droplets comprising substances, in particular medical ones, from passing through theprotective structure 21 and increase the vaporization rate of the device 1 at thesame time may be done by directly heating the protective structure. ln anembodiment of the invention, the heating to prevent the above aerosol/dropletsfrom passing through the protective structure and increase the vaporization rate ofthe device at the same time may be done by indirectly heating the protectivestructure. ln another embodiment of the invention, the heating to prevent theabove described aerosol/droplets from passing through the protective structureand increase the vaporization rate of the device 1 at the same time may be doneby indirectly heating the demister 21, if the protective structure comprises ademister, by increasing the temperature of the protective structure so that theprotective structure by means of radiant heat and/or therma| conductivity and/orconvection and/or induction heating. Another embodiment of the inventionachieves the heating to prevent the above defined aerosol/droplets from passingthrough the protective structure and increase the vaporization rate of the device 1at the same time by directly heating the demister 21, if the protective structurecomprises a demister or is in itself a demister, by increasing the temperature of the demister by means of therma| conductivity and/or induction heating.
    At least one or more protective structures 21 and/or at least one or moredemisters 21 is utilized in the device 1 and method according to the invention tomaintain or even improve the prevention of aerosols/droplets comprisingsubstances, in particular medical ones, from passing through the protectivestructure/demister 21 and increase the vaporization rate of the device 1 at the same time.
    As discussed above in conjunction with Fig. 1, the received urine may also becollected in the auxiliary heating unit/ microorganism sterilization unit prior totransferring it to the vaporization chamber 6. This auxiliary heating unit isarranged to heat up the received urine to a temperature exceeding 60 °C for a time that is sufficient to kill microorganisms in step S40. ln this way, bacteria and 26viruses that may be present in the urine can be destroyed. As discussed above in conjunction with Figs. 2a and 2b, the generated vapor is led through the vapor-pervious, protective structure 21 in step S70, and condensed downstream of saidprotective structure in step S80. The condensed vapor has no or at least reducedor even a very low concentration of unwanted substances, in particular medical substances, such as the medical ones described in this disclosure.
    The amount of im purities, i.e. non-water molecules, in the condensed vapor maysubsequently be determined. By way of example, this may be achieved throughmeasuring conductivity of the condensed vapor or by determining its absorbance.Hereby, a suitable way of continuously controlling the quality of the isolationprocess is obtained. The calculated data may be registered, and presented to thedevice operator via the control panel so as to enable online monitoring of theprecision, i.e. the quality, of the isolation process. ln order to facilitate propercontrol of the process, measurements may additionally be carried out upstream inthe process, for example prior the vaporization chamber 6. Such measurements may be used to assist the control of dosing units such as urease dosing unit. The above mentioned measurements is preferably carried out by the analytical unit 27. ln a further embodiment (not shown), a non-corrosive antifoaming agent is added in order to reduce foaming. Normally said agent is added to the boiling urine. ln an alternative em bodiment (not shown), the transfer of the urine between theurine receiving unit 3, the vaporization chamber 6 and the waste receivingcontainer 9, and optionally at least the auxiliary heating unit 31, is gravity-assisted. Accordingly, in this em bodiment all the receptacles are positioned alonga vertical line such that an outlet of an upper receptacle, e.g. the vaporizationchamber, is arranged in connection with an inlet of a lower receptacle, in theexem plary case the receiving container. The opening and closing of the valvesarranged between the receptacles could then be actuated by the weight of the fluid content of each receptacle. An extremely simple solution, not depending on 27the functioning of neither the control unit nor the pump for transferring of the content of the respective receptacle is hereby obtained. lt is to be understood that the device and/or the method according to any one ofthe above discussed embodiments of the present invention may without departingfrom the original inventive concept be used outside of the hospital environment,by way of example on a cattle or pig farm or in connection with a waste treatmentplant. Obviously, each such application would be a scaled-up version of the device intended for hospital use.
    Example 1Frozen MIS seq-opt E Coli are placed on an agar plate and incubated over night at 37 degrees C. The next day, one bacterial colony is placed in liquid growthmedium. One day later 100 microliters are placed on several agar plates,respectively. On each of these plates, a mast disc impregnated with 20 microlitersCiprofloxacine solution was placed. LB agar plates (Sigma Aldrich) 35 g/liter, LB Broth 20 g/l.
    Five control discs with 100, 10, 1, 0.1, and 0.01 mg/I were prepared. ln addition,urine containing Ciprofloxacine (100 mg/I) was processed in the device. Four samples were tested in the above bacterial model.
    Sample 1: Antibacterial effect by control Ciprofloxacine solution (100 mg/I).Sample 2: Antibacterial effect by condensed vapor from the device m aprotective structure.
    Sample 3: Antibacterial effect by condensed vapor from the device ß aprotective structure.
    Sample 4: Antibacterial effect by the remaining solution in the vaporization chamber.
    The next day, the size of the bacteria-free ring around the Ciprofloxacine- impregnated mast disc was evaluated. 28 Results: Ciproflaxine (mg/I) Bacterial inhibition zone (mm) SD100 36.7 1.510 30.3 1.21 21.7 1.20.1 9 10.01 0 0Sample 1 37 0Sample 2 27 1.1Sample 3 11 0.6Sample 4 41 1.5 Liquid that passed through the device that lacked protective structure (Sample 2)had a bacterial inhibition zone of 26 mm, which approximately corresponds to 5 mg/I Ciproflaxine.
    Liquid that passed through the device that employed a protective structure(Sample 3) had a bacterial inhibition zone of 11 mm, which approximatelycorresponds to 0.1 mg/I Ciproflaxine. Conclusively, the presence ofa protectivestructure reduced the antibiotic concentration in the condensed vapor by about 50times, demonstrating the importance of the protective structure to obtain aneffective isolation of substances by the device. Consequently, the inventionprovides a great variety of possible designs and adaptation of a device for isolation of material present in urine.
    The teaching of this invention has numerous advantages. Different em bodimentsor im plementations may yield one or more of the following advantages. lt shouldbe noted that this is not an exhaustive list and there may be other advantages notdescribed herein. One advantage of the teaching of this application is that it provides a great flexibility in designing and operating the disclosed system.
    Moreover, due to its flexibility and limited space requirement the invention may be utilized in existing industries, which do not already have such an inventive system.
    权利要求:
    Claims (20)
    [1] 1. Processanordning (1) för isolering av material, sàsom oönskade medicinska substanser, närvarande i upplöst tillstànd i urin frän människa eller djur, vilken processanordning innefattar: - en urinmottagningsenhet (3), - en vaporiseringskammare (6) som är i fluidkommunikation medurinmottagningskammaren (3), - organ, sàsom en pump (15), för reducering av trycket i vaporiseringskammaren(6) till under atmosfärstryck, - en uppvärmningsenhet (31) för uppvärmning av vaporiseringskammaren (6), - en doseringsenhet för tillsättning av ett icke-korrosivt skumförhindrande medel ivaporiseringskammaren (6), - en àngevakueringsenhet (7) som är i fluidförbindelse medvaporiseringskammaren (6) för att motta ànga därifràn, och - en avfallsutsläppsanordning (9) för att släppa ut avfall fràn vaporiseringskammaren (6), kännetecknad av: att processanordningen (1) vidare innefattar ätminstone en skyddsstruktur (21) som är i förbindelse med ängevakueringsenheten (7), vilken skyddsstruktur (21) är: - ängpermeabel, - inrättade att arbeta som en imborttagare för att hindra imbildandevätskedroppar, innefattande sädana som bär nämnda material, att passeragenom, och - uppvärmd för att förhindra att ànga kondenserar vid skyddsstrukturen (21),och att avfallsutsläppsanordningen innefattar en utbytbar avfallsbehällare (9) inrättadatt motta och isolera avfall som bildas i vaporiseringskammaren (6) genom vaporisering av urin, Claim translation - 3127243 v2.DOCX - vilken utbytbara avfallsbehàllare (9) stär i vätskeförbindelse medvaporiseringskammaren (6) för att kvarhàlla det isolerade avfallet däri, innefattande nämnda material.
    [2] 2. Processanordning enligt krav 1, varvid ätminstone tvà skyddsstrukturer (21) är kopplade i serie och/eller parallellt med varandra.
    [3] 3. Processanordning enligt krav 1, varvid skyddsstrukturen (21) innefattar ett flertal porösa och deformerbara fyllkroppar.
    [4] 4. Processanordning enligt krav 3, varvid de porösa och deformerbara fyllkropparna är tillverkade av stàlull eller av ett polymersvampmaterial.
    [5] 5. Processanordning enligt krav 1, varvid skyddsstrukturen innefattar ett metalnät med fasta avstànd mellan metalltràdarna.
    [6] 6. Processanordning enligt krav 1, varvid skyddsstrukturen innefattar baffelenheter eller väsentligen tvädimensionella styva objekt.
    [7] 7. Processanordning enligt krav 1, vidare innefattande en ureas-doseringsenhet.
    [8] 8. Processanordning enligt krav 1, vidare innefattande en kondenseringsenhet (24) för mottagning av änga frän ängevakueringsenheten (7).
    [9] 9. Processanordning enligt krav 8, vidare innefattande en förbindelse för att släppaut av kondenseringsenheten (24) kondenserad vätska i ett avloppssystem via ett dräneringsavlopp (28).10. Processanordning enligt krav 8, vidare innefattande en analysenhet (27) som är anordnad nedströms skyddsstrukturen (21) och som är inrättad att bestämmagraden av orenheter i ett kondensat som utvinns fràn kondenseringsenheten (7).
    [10] 10. Claim translation - 3127243 v2.DOCX
    [11] 11. Processanordning enligt krav 1, vidare innefattande en mikroorganism-reduceringsenhet (12) som är inrättad att värma upp den mottagna urinen till entemperatur överskridande 60 °C.
    [12] 12. Processanordning enligt krav 1, vidare innefattande en pump (15) för reducering av trycket i vaporiseringskammaren (6) till under atmosfärstryck.
    [13] 13. Processanordning enligt krav 1, vidare innefattande en doseringsenhet för tillsättning av ett icke-korrosivt skumförhindrande ämne i vaporiseringskammaren (e).
    [14] 14. Processanordning enligt krav 1, dimensionerad och hopsatt som en enhet lämpad för mobil användning inomhus, säsom i ett sjukhus.
    [15] 15. l/letod för isolering av material, säsom oönskade medicinska substanser, närvarande i upplöst tillstànd i urin frän människa eller djur, vilken metod innefattar: - att motta (S 10) urin, - att överföra (S20) den mottagna urinen till en vaporiseringskammare (6), - att utsätta urinen för temperaturer som är tillräckliga för att vaporisera urinen,- att evakuera (S60) änga som bildats i vaporiseringskammaren (6) in i enevakueringsenhet (7), kännetecknad av: - att leda den i vaporiseringskammaren (6) bildade ängan genom enàngpermeabel skyddsstruktur som är inrättad att arbeta som enimborttagare för att hindra imbildande vätskedroppar, innefattande de sombär nämnda material, frän att passera genom evakueringsenheten (7), - att ytterligare värma upp ängan som passerar genom skyddsstrukturen föratt hindra ängan frän att kondensera vid skyddsstrukturen (21), och - att överföra avfallet som bildas i vaporiseringskammaren (6) till en utbytbaravfallsbehällare (9) där avfallet isoleras och kvarhälls, inklusive nämnda material.
    [16] 16. l/letod enligt krav 15, vidare innefattande: Claim translation - 3127243 v2.DOCX - att utsätta urinen för ett tryck under atmosfärstryck i vaporiseringskammaren (e).
    [17] 17. Metod enligt krav 15, vidare innefattande:- att reducera mängden urea i den urin som finns i vaporiseringskammaren (6) genom att behandla urinen med ureas.
    [18] 18. l/letod enligt krav 15, vidare innefattande:- att bestämma mängden av orenheter i den evakuerade ängan, genom attanvända ett kondensat av änga som har passerat genom skyddsstrukturen(21).
    [19] 19. l/letod enligt krav 15, varvid den i vaporiseringskammaren (6) mottagna urinen värms upp till en temperatur överskridande 60 °C innan den överförs vidare.
    [20] 20. l/letod enligt krav 15, vidare innefattande: - att tillsätta ett icke-korrosivt skumförhindrande medel till vaporiseringskammaren (6) för att förhindra skumbildning. Claim translation - 3127243 v2.DOCX
    类似技术:
    公开号 | 公开日 | 专利标题
    Godfree et al.2005|Processes for managing pathogens
    Pesaro et al.1995|In situ inactivation of animal viruses and a coliphage in nonaerated liquid and semiliquid animal wastes
    SE1551420A1|2017-05-04|Device and method for isolation of potentially harmful material present in human or animal urine
    Hill et al.2003|Performance of swine waste lagoons for removing Salmonella and enteric microbial indicators
    EP3615474B1|2021-03-17|Method and apparatus for isolation of potentially harmful material
    Iranpour et al.2006|Thermophilic‐Anaerobic Digestion to Produce Class A Biosolids: Initial Full‐Scale Studies at Hyperion Treatment Plant
    Yu et al.2013|Design and running for a hospital wastewater treatment project
    CN201485298U|2010-05-26|Sewage sterilizer
    CN108706666A|2018-10-26|A kind of precursor virus that eliminates off infects latent quick-reaction system
    US20200140287A1|2020-05-07|Method and system for treating blackwater containing medical substances
    Chang2015|Evaluation of multiple disinfection methods to mitigate contaminated irrigation water
    Smith Jr et al.2008|Disinfection processes and stability refinements to biosolids treatment technologies
    CN208603957U|2019-03-15|A kind of sewage-treatment plant for medical sewage
    Kim et al.2015|Inactivation effect according to the thermophilic aerobic oxidation process of encephalomyocarditis virus in swine manure
    CN205398294U|2016-07-27|Pure water preparation system
    CN211896558U|2020-11-10|Triple degree of depth degassing unit of hospital's waste water
    Reynolds et al.1974|Thermoradiation treatment of sewage sludge using reactor waste fission products
    Zdeb et al.2018|Disinfection of rainwater as a way to their microbiological stability and safe use
    DE102017005251A1|2018-12-06|Process for the environmentally friendly direct processing of organic waste, in particular liquid manure, solid manure, fermentation residues, flotates, manure, manure, slaughterhouse waste, sewage sludge, straw, remnants of debris for the production of energy, fertilizer and process water. |
    CN105776575B|2019-03-26|High activity enzyme antisepsis and sterilization deodorant and its preparation process, application
    US10577268B2|2020-03-03|Method for treating dangerous liquids for dumping
    CN109319954A|2019-02-12|Hospital sewage and sludge are automatically separated filtration system
    Hill Jr et al.1971|Viral disinfection of estuarine water by UV
    CN111689645A|2020-09-22|Intensified sewage treatment method for infectious disease hospital
    Daugelat et al.2008|The design and testing of a continuous effluent sterilization system for liquid waste
    同族专利:
    公开号 | 公开日
    EP3370841A1|2018-09-12|
    SE540041C2|2018-03-06|
    WO2017076745A1|2017-05-11|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3506543A|1964-07-13|1970-04-14|Whirlpool Co|Urine recovery process by thermoelectric distillation and filtration|
    FR2260549B1|1974-02-11|1978-06-16|Saint Gobain Techn Nouvelles|
    US4316774A|1979-07-05|1982-02-23|United Technologies Corporation|Thermoelectric integrated membrane evaporation system|
    US5273719A|1988-05-10|1993-12-28|Japanic Corporation|Urine treating device|
    AU653565B2|1990-12-21|1994-10-06|Nikken Corporation|Raw sewage disposal apparatus and prefab for accomodating the same|
    WO2007008491A2|2005-07-06|2007-01-18|Sylvan Source, Inc.|Water purification system|
    US20100288619A1|2008-01-18|2010-11-18|Takashi Yabe|Energy-Saving Type Apparatus For Producing Freshwater|
    US20120055777A1|2010-09-03|2012-03-08|Liquidbreaker Llc.|Distillation Urine Recycling Systems and Methods|
    SE1250833A1|2012-07-13|2014-01-14|Ingela Skogvall Svensson|Absorbent unit|SE539233C2|2015-11-02|2017-05-23|Pharmalundensis Ab|Method and apparatus to reduce waste production in an isolation process|
    EP3615474B1|2017-04-28|2021-03-17|PharmaLundensis AB|Method and apparatus for isolation of potentially harmful material|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    SE1551420A|SE540041C2|2015-11-03|2015-11-03|Device and method for isolation of material present in human urine|SE1551420A| SE540041C2|2015-11-03|2015-11-03|Device and method for isolation of material present in human urine|
    EP16794232.5A| EP3370841A1|2015-11-03|2016-10-27|Device and method for isolation of potentially harmful material present in human or animal urine|
    PCT/EP2016/075957| WO2017076745A1|2015-11-03|2016-10-27|Device and method for isolation of potentially harmful material present in human or animal urine|
    [返回顶部]